ALSO IN THIS MONTH'S ISSUE

• Implementation Of MFN, Importation, And Other Mischief In 2020

  As the election nears and a potential change in power of both the White House and Congress approaches, it is important to understand that significant healthcare policy can still be accomplished this year.

• Changing The Status Quo Regarding Diversity In Clinical Trials

  Encouraging patients of all races and genders to enroll in clinical trials has been a challenge for years. So, what can be done?

• Why COGs Will Demand More Attention From Biosimilar Makers

  Without continued innovation in the manufacturing and analytical components of biosimilar development, the biosimilar value proposition becomes less feasible for pharma manufacturers.

• Companies To Watch: Osivax

  Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Preclinical studies also have started on a coronavirus vaccine, which would include Covid-19.